EMEA-001451-PIP01-13-M01 - paediatric investigation plan

tildrakizumab

Key facts

• Invented name:
  Ilumetri
• Active Substance:
  tildrakizumab
• Therapeutic area:
  Dermatology
• Decision number:
  P/0120/2021
• PIP number:
  EMEA-001451-PIP01-13-M01
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of psoriasis
• Route(s) of administration:
  Subcutaneous use
• Contact for public enquiries:

  Almirall, S.A

  E-mail: [e-mail]; Tel: [phone]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  17/03/2021

Decision

P/0120/2021 : EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for tildrakizumab (Ilumetri) (EMEA-001451-PIP01-13-M01)

Reference Number: EMA/93320/2021